RITUXIMAB IS A MONOCLONAL ANTIBODY USED IN THE TREATMENT OF CERTAIN TYPES OF HAEMATOLOGICAL MALIGNANCIES. WHICH ANTIGEN DOES IT TARGET

March 28, 2024

A. CD56
B. CD20 ✓
C. CD4
D. CD8

Rituximab targets CD20, which is a specific B-cell surface antigen. In other words, Rituximab targets the CD20 antigen. CD20 is a cell surface protein that is primarily expressed on B cells, making it an ideal target for rituximab in the treatment of B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.